Wegovy (Semaglutide Injection 2.4 mg)

Wegovy (semaglutide 2.4 mg) is the only weight-loss drug with a proven cardiovascular benefit, reducing major adverse cardiac events by 20% in the SELECT trial of 17,604 non-diabetic adults. As a pure GLP-1 receptor agonist, it achieves 14.9% average weight loss at 68 weeks in the STEP 1 trial — roughly 34 pounds — but trails #1 Zepbound's 20.9% efficacy. However, Wegovy's landmark cardiovascular risk-reduction indication, approved in March 2024, provides unmatched heart protection. Weekly doses escalate over 16-20 weeks to minimize side effects, and monthly list price is approximately $1,349, with savings programs reducing costs to $25 per month for eligible patients.